Latest Oculus Innovative Sciences (OCLS) Headlines
Post# of 42
Posted On: 03/13/2014 12:34:54 AM
Latest Oculus Innovative Sciences (OCLS) Headlines
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Feb 28, 7:02AM CST
These under-$10 stocks are within range of triggering breakout trades.
Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board of Directors
GlobeNewswire - Thu Feb 27, 8:52AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Russell ("Russ") Harrison to its board of directors, effective February 26, 2014.
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Company To Provide Video Surveillance & Security Platform for Marijuana Facilities in Rapidly Evolving Cannabis Industry
PR Newswire - Thu Feb 20, 7:45AM CST
Medical marijuana briefing: companies prepare for increased production as sector quickly expands: DirectView Holdings, Inc. (OTC: DIRV), PetroTech Oil and Gas, Inc. (OTC: PTOG), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS)
Oculus Innovative Sciences Receives Approval for Oral and Throat Infection Products in Mexico
GlobeNewswire - Wed Feb 19, 7:10AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries, today announced a regulatory approval in Mexico for the company's new Microcyn60(R) Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections.
Oculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014
GlobeNewswire - Thu Feb 13, 3:05PM CST
-- Microcyn(R) Scar Management HydroGel Approved by FDA in U.S. and Ministry of Health in Mexico During Quarter
Oculus Innovative Sciences Announces Completion of Agreements Required for IPO by Company's Subsidiary, Ruthigen, Inc.
GlobeNewswire - Thu Feb 06, 3:05PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that as of January 31, 2014, Oculus has entered into certain new and amended agreements with its wholly owned subsidiary, Ruthigen Inc., which are required for Ruthigen's continued IPO process.
Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate Acne
GlobeNewswire - Tue Feb 04, 9:48PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries, today announced receipt of the European CE Mark for the Microcyn(R)-based GramaDerm(R) Solution and GramaDerm(R) Hydrogel. Both products are intended for use in the topical treatment of mild to moderate acne and are designed to complement other acne treatments.
Waterjet Holdings, Inc. Completes the Acquistion of Flow International Corporation
GlobeNewswire - Fri Jan 31, 2:07PM CST
Waterjet Holdings, Inc., an entity affiliated with American Industrial Partners ("AIP"), completed the acquisition of Flow International Corporation ("Flow" or the "Company") on January 31, 2014. The investment in Flow (Nasdaq:FLOW) was made out of American Industrial Partners Capital Fund V, LP a $717.5 million fund that closed in December 2011. Under the terms of the merger agreement, Waterjet Holdings, Inc. acquired all of the outstanding shares of Flow common stock for $4.05 per share in cash. Terms of the acquisition were first announced on September 25, 2013.
Oculus Innovative Sciences Announces Fiscal Third Quarter 2014 Financial Results and Conference Call
GlobeNewswire - Thu Jan 30, 7:08AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the financial results for its fiscal third quarter 2014, ended December 31, 2013, will be released after the U.S. market closes on February 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on February 13, 2014, to discuss fiscal third quarter results.
Oculus Introduces Two Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 4:10PM CST
Oculus launched two new Microcyn-based advanced wound care products in the U.S.
Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care Products for U.S. Prescription Wound Care Market
GlobeNewswire - Tue Jan 07, 7:10AM CST
-- New three-ounce Microcyn(R) Skin & Wound Spray HydroGel delivers wound hydrogel to entire wound site via innovative spray application
Oculus Innovative Sciences Receives Notification of Compliance With the Stockholders' Requirement of the NASDAQ Listing Rules
GlobeNewswire - Mon Dec 30, 7:08AM CST
Oculus Innovative Sciences (Nasdaq:OCLS) today announced it received a determination letter from the listing qualifications department of the NASDAQ Stock Market LLC ("NASDAQ") notifying the company that it is now compliant with the stockholders' equity requirement for continued listing on the Nasdaq Capital Market and is no longer subject to delisting at this time.
Oculus Innovative Sciences Pays Off Debt to Strengthen Balance Sheet; Obtains $4.5 Million in Stockholders' Equity on a Pro Forma Basis as of September 30, 2013, Sufficient to Regain Compliance with NASDAQ Listing Rules
GlobeNewswire - Thu Dec 19, 7:08AM CST
In a transaction on October 30, 2012, Oculus Innovative Sciences (Nasdaq:OCLS) agreed to issue $3.5 million dollars of restricted common stock to its primary lender, Venture Lending and Leasing (VLL), which agreed to reduce the company's debt liability with the sale of these common shares. As of December 16, 2013, VLL sold all of its shares of the company's common stock acquired in the October 30, 2012, transaction at an average price of about $5.35 per share. The net proceeds of the shares will be applied to the put warrant liabilities of those certain warrants held by VLL, and will also prepay the remaining balance of principal and interest owed by the company under those certain loan agreements with VLL. The net result of this transaction is intended to increase the company's stockholders' equity by $1 million. This also reduced Oculus' debt to less than $60,000.
Surgical Scar Market Is Ripe for Innovation
ACCESSWIRE - Wed Dec 18, 10:15AM CST
Scarring is an inevitable consequence of dermal wounds - such as those incurred during routine surgeries - that has a profound impact on physical appearance and psychological well-being. Despite high demand for therapies that prevent or reduce dermal scarring, there are few treatment options approved by the U.S. Food & Drug Administration ("FDA"), which has led to significant investor appetite for companies targeting the space. For instance, Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) recently doubled in price after receiving FDA 510(k) approval for its Microcyn Scar Management HydroGel on December 4, 2013.
Updated Estimates, Stock Movements, and Regulatory Approvals - Research Report on Quest Diagnostics, Zimmer Holdings, Pacira Pharmaceuticals, Geron, and Oculus Innovative Sciences
PR Newswire - Wed Dec 18, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Zimmer Holdings, Inc. (NYSE: ZMH), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Geron Corporation (NASDAQ: GERN), and Oculus Innovative Sciences, Inc. (NASDAQ: OCLS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Ampio's Failed Drug Partner Talks Forces Spin-Out Plan
at The Street - Mon Dec 16, 7:18AM CST
The formation of Viryx Pharma comes only after Ampio couldn't find a partner for its premature ejaculation drug Zertane.
Oculus Innovative Sciences Inc awarded regulatory approval for new Microcyn based scar management hydrogel in Mexico
M2 - Fri Dec 13, 5:24AM CST
Healthcare company Oculus Innovative Sciences Inc (NasdaqCM:OCLS) reported on Thursday the receipt of regulatory approval for its new Microcyn based scar management hydrogel under the brand name Epicyn in Mexico.
Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars
GlobeNewswire - Thu Dec 12, 7:08AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products 27 countries, today announced a regulatory approval in Mexico for the company's new Microcyn(R)-based scar management hydrogel, under the brand name Epicyn(TM).
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Feb 28, 7:02AM CST
These under-$10 stocks are within range of triggering breakout trades.
Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board of Directors
GlobeNewswire - Thu Feb 27, 8:52AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Russell ("Russ") Harrison to its board of directors, effective February 26, 2014.
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Company To Provide Video Surveillance & Security Platform for Marijuana Facilities in Rapidly Evolving Cannabis Industry
PR Newswire - Thu Feb 20, 7:45AM CST
Medical marijuana briefing: companies prepare for increased production as sector quickly expands: DirectView Holdings, Inc. (OTC: DIRV), PetroTech Oil and Gas, Inc. (OTC: PTOG), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS)
Oculus Innovative Sciences Receives Approval for Oral and Throat Infection Products in Mexico
GlobeNewswire - Wed Feb 19, 7:10AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries, today announced a regulatory approval in Mexico for the company's new Microcyn60(R) Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections.
Oculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014
GlobeNewswire - Thu Feb 13, 3:05PM CST
-- Microcyn(R) Scar Management HydroGel Approved by FDA in U.S. and Ministry of Health in Mexico During Quarter
Oculus Innovative Sciences Announces Completion of Agreements Required for IPO by Company's Subsidiary, Ruthigen, Inc.
GlobeNewswire - Thu Feb 06, 3:05PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that as of January 31, 2014, Oculus has entered into certain new and amended agreements with its wholly owned subsidiary, Ruthigen Inc., which are required for Ruthigen's continued IPO process.
Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate Acne
GlobeNewswire - Tue Feb 04, 9:48PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries, today announced receipt of the European CE Mark for the Microcyn(R)-based GramaDerm(R) Solution and GramaDerm(R) Hydrogel. Both products are intended for use in the topical treatment of mild to moderate acne and are designed to complement other acne treatments.
Waterjet Holdings, Inc. Completes the Acquistion of Flow International Corporation
GlobeNewswire - Fri Jan 31, 2:07PM CST
Waterjet Holdings, Inc., an entity affiliated with American Industrial Partners ("AIP"), completed the acquisition of Flow International Corporation ("Flow" or the "Company") on January 31, 2014. The investment in Flow (Nasdaq:FLOW) was made out of American Industrial Partners Capital Fund V, LP a $717.5 million fund that closed in December 2011. Under the terms of the merger agreement, Waterjet Holdings, Inc. acquired all of the outstanding shares of Flow common stock for $4.05 per share in cash. Terms of the acquisition were first announced on September 25, 2013.
Oculus Innovative Sciences Announces Fiscal Third Quarter 2014 Financial Results and Conference Call
GlobeNewswire - Thu Jan 30, 7:08AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the financial results for its fiscal third quarter 2014, ended December 31, 2013, will be released after the U.S. market closes on February 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on February 13, 2014, to discuss fiscal third quarter results.
Oculus Introduces Two Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 4:10PM CST
Oculus launched two new Microcyn-based advanced wound care products in the U.S.
Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care Products for U.S. Prescription Wound Care Market
GlobeNewswire - Tue Jan 07, 7:10AM CST
-- New three-ounce Microcyn(R) Skin & Wound Spray HydroGel delivers wound hydrogel to entire wound site via innovative spray application
Oculus Innovative Sciences Receives Notification of Compliance With the Stockholders' Requirement of the NASDAQ Listing Rules
GlobeNewswire - Mon Dec 30, 7:08AM CST
Oculus Innovative Sciences (Nasdaq:OCLS) today announced it received a determination letter from the listing qualifications department of the NASDAQ Stock Market LLC ("NASDAQ") notifying the company that it is now compliant with the stockholders' equity requirement for continued listing on the Nasdaq Capital Market and is no longer subject to delisting at this time.
Oculus Innovative Sciences Pays Off Debt to Strengthen Balance Sheet; Obtains $4.5 Million in Stockholders' Equity on a Pro Forma Basis as of September 30, 2013, Sufficient to Regain Compliance with NASDAQ Listing Rules
GlobeNewswire - Thu Dec 19, 7:08AM CST
In a transaction on October 30, 2012, Oculus Innovative Sciences (Nasdaq:OCLS) agreed to issue $3.5 million dollars of restricted common stock to its primary lender, Venture Lending and Leasing (VLL), which agreed to reduce the company's debt liability with the sale of these common shares. As of December 16, 2013, VLL sold all of its shares of the company's common stock acquired in the October 30, 2012, transaction at an average price of about $5.35 per share. The net proceeds of the shares will be applied to the put warrant liabilities of those certain warrants held by VLL, and will also prepay the remaining balance of principal and interest owed by the company under those certain loan agreements with VLL. The net result of this transaction is intended to increase the company's stockholders' equity by $1 million. This also reduced Oculus' debt to less than $60,000.
Surgical Scar Market Is Ripe for Innovation
ACCESSWIRE - Wed Dec 18, 10:15AM CST
Scarring is an inevitable consequence of dermal wounds - such as those incurred during routine surgeries - that has a profound impact on physical appearance and psychological well-being. Despite high demand for therapies that prevent or reduce dermal scarring, there are few treatment options approved by the U.S. Food & Drug Administration ("FDA"), which has led to significant investor appetite for companies targeting the space. For instance, Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) recently doubled in price after receiving FDA 510(k) approval for its Microcyn Scar Management HydroGel on December 4, 2013.
Updated Estimates, Stock Movements, and Regulatory Approvals - Research Report on Quest Diagnostics, Zimmer Holdings, Pacira Pharmaceuticals, Geron, and Oculus Innovative Sciences
PR Newswire - Wed Dec 18, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Zimmer Holdings, Inc. (NYSE: ZMH), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Geron Corporation (NASDAQ: GERN), and Oculus Innovative Sciences, Inc. (NASDAQ: OCLS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Ampio's Failed Drug Partner Talks Forces Spin-Out Plan
at The Street - Mon Dec 16, 7:18AM CST
The formation of Viryx Pharma comes only after Ampio couldn't find a partner for its premature ejaculation drug Zertane.
Oculus Innovative Sciences Inc awarded regulatory approval for new Microcyn based scar management hydrogel in Mexico
M2 - Fri Dec 13, 5:24AM CST
Healthcare company Oculus Innovative Sciences Inc (NasdaqCM:OCLS) reported on Thursday the receipt of regulatory approval for its new Microcyn based scar management hydrogel under the brand name Epicyn in Mexico.
Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars
GlobeNewswire - Thu Dec 12, 7:08AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products 27 countries, today announced a regulatory approval in Mexico for the company's new Microcyn(R)-based scar management hydrogel, under the brand name Epicyn(TM).
(0)
(0)
